Review

Type of diabetes mellitus: Does it matter to the clinician?

Byron J. Hoogwerf, MD, FACP, FACE
Cleveland Clinic Journal of Medicine February 2020, 87 (2) 100-108; DOI: https://doi.org/10.3949/ccjm.87a.19020

CME/MOC

  • Release date: February 1, 2020
  • Expiration date: January 31, 2021
CME/MOC Accreditation Information.

ABSTRACT

The classification of diabetes mellitus in 2020 still starts with 2 major types, ie, type 1 and type 2, but each of these now includes a few uncommon variants. Understanding the many faces of the diabetes syndrome can make a difference in how clinicians select glucose-lowering therapy.

Footnotes

  • Dr. Hoogwerf has disclosed formerly being an employee of and currently owning stock in Eli Lilly and consulting for Mannkind Corp.

View Full Text

CME/MOC

Clicking the link below will connect you to begin the credit-claiming process for CME and MOC. After clicking on the link, scroll to the bottom of the page and click on “Complete the CME/MOC Process.” You will need your myCME login information to access this.

Click here to complete the CME/MOC process.

REFERENCES

  1. ↵
    1. Anonymous
    . Insulin and diabetes: the types for which cure is in sight. Hosp Health Rev 1923; 2(16):78–79. pmid:29418321
    OpenUrl
  2. ↵
    1. Bliss M
    . The Discovery of Insulin. Chicago, IL: University of Chicago Press; 1963.
  3. ↵
    1. Zhang H,
    2. Pollin TI
    . Epigenetics variation and pathogenesis in diabetes. Curr Diab Rep 2018; 18(11):121. doi:10.1007/s11892-018-1091-4
    OpenUrlCrossRef
    1. Sircana A,
    2. Framarin L,
    3. Leone N, et al
    . Altered gut microbiota in type 2 diabetes: just a coincidence? Curr Diab Rep 2018; 18(10):98. doi:10.1007/s11892-018-1057-6
    OpenUrlCrossRef
    1. Chen X,
    2. Devaraj S
    . Gut microbiome in obesity, metabolic syndrome, and diabetes. Curr Diab Rep 2018; 18(12):129. doi:10.1007/s11892-018-1104-3
    OpenUrlCrossRef
  6. ↵
    1. Ahlqvist E,
    2. Storm P,
    3. Karajamaki A, et al
    . Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol 2018; 6(5):361–369. doi:10.1016/S2213-8587(18)30051–2
    OpenUrlCrossRef
    1. Dorajoo R,
    2. Liu J,
    3. Boehm BO
    . Genetics of type 2 diabetes and clinical utility. Genes (Basel) 2015; 6(2):372–384. doi:10.3390/genes6020372
    OpenUrlCrossRef
  8. ↵
    1. Raz I,
    2. Riddle MC,
    3. Rosenstock J, et al
    . Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors’ Expert Forum. Diabetes Care 2013; 36(6):1779–1788. doi:10.2337/dc13-0512
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Stancakova A,
    2. Laakso M
    . Genetics of type 2 diabetes. Endocr Dev 2016; 31:203–220. doi:10.1159/000439418
    OpenUrlCrossRefPubMed
  10. ↵
    1. Hanson MA,
    2. Godfrey KM
    . Genetics: epigenetic mechanisms underlying type 2 diabetes mellitus. Nat Rev Endocrinol 2015; 11(5):261–262. doi:10.1038/nrendo.2015.31
    OpenUrlCrossRef
  11. ↵
    1. American Diabetes Association
    . 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2019. Diabetes Care 2019; 42(suppl 1):S13–S28. doi:10.2337/dc19-S002
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Lawrence RD
    . Types of human diabetes. Br Med J 1951; 1(4703):373–375. doi:10.1136/bmj.1.4703.373
    OpenUrlFREE Full Text
  13. ↵
    1. Himsworth HP
    . Diabetes mellitus: its differentiation into insulin-sensitive and insulin-insensitive types. Diabet Med 2011; 28(12):1440–1444. doi:10.1111/j.1464-5491.2011.3508.x
    OpenUrlCrossRefPubMed
  14. ↵
    1. Kota SK,
    2. Meher LK,
    3. Jammula S,
    4. Kota SK,
    5. Modi KD
    . Genetics of type 2 diabetes mellitus and other specific types of diabetes; its role in treatment modalities. Diabetes Metab Syndr 2012; 6(1):54–58. doi:10.1016/j.dsx.2012.05.014
    OpenUrlCrossRefPubMed
  15. ↵
    1. Malecki MT,
    2. Mlynarski W
    . Monogenic diabetes: implications for therapy of rare types of disease. Diabetes Obes Metab 2008; 10(8):607–616. doi:10.1111/j.1463-1326.2007.00736.x
    OpenUrlCrossRefPubMed
  16. ↵
    1. Mihai B,
    2. Mihai C,
    3. Cijevschi-Prelipcean C,
    4. Lacatusu C
    . Rare types of diabetes mellitus. Rev Med Chir Soc Med Nat Iasi 2012; 116(3):700–707. pmid:23272513
    OpenUrl
  17. ↵
    1. Shields BM,
    2. Shepherd M,
    3. Hudson M, et al. UNITED study team
    . Population-based assessment of a biomarker-based screening pathway to aid diagnosis of monogenic diabetes in young-onset patients. Diabetes Care 2017; 40(8):1017–1025. doi:10.2337/dc17-0224
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Todd JN,
    2. Srinivasan S,
    3. Pollin TI
    . Advances in the genetics of youth-onset type 2 diabetes. Curr Diab Rep 2018; 18(8):57. doi:10.1007/s11892-018-1025-1
    OpenUrlCrossRef
  19. ↵
    1. Klupa T,
    2. Skupien J,
    3. Malecki MT
    . Monogenic models: what have the single gene disorders taught us? Curr Diab Rep 2012; 12(6):659–666. doi:10.1007/s11892-012-0325-0
    OpenUrlCrossRefPubMed
  20. ↵
    1. Pearson ER,
    2. Flechtner I,
    3. Njolstad PR, et al. Neonatal Diabetes International Collaborative Group
    . Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 2006; 355(5):467–477. doi:10.1056/NEJMoa061759
    OpenUrlCrossRefPubMed
    1. Anik A,
    2. Catli G,
    3. Abaci A,
    4. Bober E
    . Maturity-onset diabetes of the young (MODY): an update. J Pediatr Endocrinol Metab 2015; 28(3–4):251–263. doi:10.1515/jpem-2014-0384
    OpenUrlCrossRefPubMed
  22. ↵
    1. Bacon S,
    2. Kyithar MP,
    3. Rizvi SR, et al
    . Successful maintenance on sulphonylurea therapy and low diabetes complication rates in a HNF1A-MODY cohort. Diabet Med 2016; 33(7):976–984. doi:10.1111/dme.12992
    OpenUrlCrossRefPubMed
  23. ↵
    1. Bishay RH,
    2. Greenfield JR
    . A review of maturity onset diabetes of the young (MODY) and challenges in the management of glucokinase-MODY. Med J Aust 2016; 205(10):480–485. doi:10.5694/mja16.00458
    OpenUrlCrossRef
  24. ↵
    1. Steck AK,
    2. Winter WE
    . Review on monogenic diabetes. Curr Opin Endocrinol Diabetes Obes 2011; 18(4):252–258. doi:10.1097/MED.0b013e3283488275
    OpenUrlCrossRefPubMed
  25. ↵
    1. Urakami T
    . Maturity-onset diabetes of the young (MODY): current perspectives on diagnosis and treatment. Diabetes Metab Syndr Obes 2019 Jul 8; 12:1047–1056. doi:10.2147/DMSO.S179793
    OpenUrlCrossRef
  26. ↵
    1. Banerji MA
    . Impaired beta-cell and alpha-cell function in African-American children with type 2 diabetes mellitus—”Flatbush diabetes”. J Pediatr Endocrinol Metab 2002; 15(suppl 1):493–501. pmid:12017222
    OpenUrl
  27. ↵
    1. Banerji MA,
    2. Chaiken RL,
    3. Huey H, et al
    . GAD antibody negative NIDDM in adult black subjects with diabetic ketoacidosis and increased frequency of human leukocyte antigen DR3 and DR4. Flatbush diabetes. Diabetes 1994; 43(6):741–745. doi:10.2337/diab.43.6.741
    OpenUrlCrossRef
  28. ↵
    1. Lebovitz HE,
    2. Banerji MA
    . Ketosis-prone diabetes (Flatbush diabetes): an emerging worldwide clinically important entity. Curr Diab Rep 2018; 18(11):120. doi:10.1007/s11892-018-1075-4
    OpenUrlCrossRef
  29. ↵
    1. Andersen MK,
    2. Hansen T
    . Genetic aspects of latent autoimmune diabetes in adults: a mini-review. Curr Diabetes Rev 2019; 15(3):194–198. doi:10.2174/1573399814666180730123226
    OpenUrlCrossRef
    1. Beyan H,
    2. Ola T,
    3. David R,
    4. Leslie G
    . Progression of autoimmune diabetes: slowly progressive insulin-dependent diabetes mellitus or latent autoimmune diabetes of adult. Ann N Y Acad Sci 2006; 1079(1):81–89. doi:10.1196/annals.1375.011
    OpenUrlCrossRefPubMed
    1. Cousminer DL,
    2. Ahlqvist E,
    3. Mishra R, et al
    . First genome-wide association study of latent autoimmune diabetes in adults reveals novel insights linking immune and metabolic diabetes. Diabetes Care 2018; 41(11):2396–2403. doi:10.2337/dc18-1032
    OpenUrlAbstract/FREE Full Text
    1. Grill V
    . LADA: a type of diabetes in its own right? Curr Diabetes Rev 2019; 15(3):174–177. doi:10.2174/1573399814666180716150905
    OpenUrlCrossRef
    1. Landin-Olsson M
    . Latent autoimmune diabetes in adults. Ann N Y Acad Sci 2002; 958(1):112–116. doi:10.1111/j.1749-6632.2002.tb02953.x
    OpenUrlCrossRefPubMed
  34. ↵
    1. Nabhan F,
    2. Emanuele MA,
    3. Emanuele N
    . Latent autoimmune diabetes of adulthood. Unique features that distinguish it from types 1 and 2. Postgrad Med 2005; 117(3):7–12. doi:10.3810/pgm.2005.03.1597
    OpenUrlCrossRefPubMed
  35. ↵
    1. Collins FS,
    2. Mansoura MK
    . The Human Genome Project. Revealing the shared inheritance of all humankind. Cancer 2001; 91(suppl 1):221–225. doi:10.1002/1097-0142(20010101)91:1+<221::aid-cncr8>3.3.co;2-0
    OpenUrlCrossRefPubMed
  36. ↵
    1. Dunston GM,
    2. Akinsete O,
    3. Collins FS
    . Diabetes project. Science 1997; 276(5315):1013. doi:10.1126/science.276.5315.1013b
    OpenUrlCrossRef
  37. ↵
    1. Kwak SH,
    2. Park KS
    . Genetics of type 2 diabetes and potential clinical implications. Arch Pharm Res 2013; 36(2):167–177. doi:10.1007/s12272-013-0021-x
    OpenUrlCrossRefPubMed
  38. ↵
    1. Sun X,
    2. Yu W,
    3. Hu C
    . Genetics of type 2 diabetes: insights into the pathogenesis and its clinical application. Biomed Res Int 2014; 2014:926713. doi:10.1155/2014/926713
    OpenUrlCrossRefPubMed
  39. ↵
    1. Handelsman Y,
    2. Oral EA,
    3. Bloomgarden ZT, et al. American Association of Clinical Endocrinologists
    . The clinical approach to the detection of lipodystrophy—an AACE consensus statement. Endocr Pract 2013; 19(1):107–116. pmid:23435042
    OpenUrlCrossRefPubMed
  40. ↵
    1. Araujo-Vilar D,
    2. Santini F
    . Diagnosis and treatment of lipodystrophy: a step-by-step approach. J Endocrinol Invest 2019; 42(1):61–73. doi:10.1007/s40618-018-0887-z
    OpenUrlCrossRef
  41. ↵
    1. Akinci B,
    2. Meral R,
    3. Oral EA
    . Update on therapeutic options in lipodystrophy. Curr Diab Rep 2018; 18(12):139. doi:10.1007/s11892-018-1100-7
    OpenUrlCrossRef
  42. ↵
    1. Motulsky AG,
    2. Beutler E
    . Population screening in hereditary hemochromatosis. Annu Rev Public Health 2000; 21:65–79. doi:10.1146/annurev.publhealth.21.1.65
    OpenUrlCrossRefPubMed
  43. ↵
    1. Waalen J,
    2. Beutler E
    . Hereditary hemochromatosis: screening and management. Curr Hematol Rep 2006; 5(1):34–40. pmid:16537044
    OpenUrlPubMed
  44. ↵
    1. DeFronzo RA
    . Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009; 58(4):773–795. doi:10.2337/db09-9028
    OpenUrlFREE Full Text
  45. ↵
    1. American Diabetes Association
    . 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2019. Diabetes Care 2019; 42(suppl 1):S90–S102. doi:10.2337/dc19-S009
    OpenUrlAbstract/FREE Full Text
  46. ↵
    1. Garber AJ,
    2. Abrahamson MJ,
    3. Barzilay JI, et al. American Association of Clinical Endocrinologists (AACE); American College of Endocrinology (ACE)
    . Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2016 executive summary. Endocr Pract 2016; 22(1):84–113. doi:10.4158/EP151126.CS
    OpenUrlCrossRefPubMed
    1. American Diabetes Association
    . 4. Comprehensive medical evaluation and assessment of comorbidities: standards of medical care in diabetes—2019. Diabetes Care 2019; 42(suppl 1):S34–S45. doi:10.2337/dc19-S004
    OpenUrlAbstract/FREE Full Text
    1. Marso SP,
    2. Daniels GH,
    3. Brown-Frandsen K, et al. LEADER Trial Investigators
    . Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375(4):311–322. doi:10.1056/NEJMoa1603827
    OpenUrlCrossRefPubMed
    1. Gerstein HC,
    2. Colhoun HM,
    3. Dagenais GR, et al. REWIND Investigators
    . Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019; 394(10193):121–130. doi:10.1016/S0140-6736(19)31149–3
    OpenUrlCrossRefPubMed
    1. Husain M,
    2. Bain SC,
    3. Jeppesen OK, et al
    . Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk. Diabetes Obes Metab 2020 Jan 5 [Epub ahead of print]. doi:10.1111/dom.13955
    OpenUrlCrossRef
    1. Pfeffer MA,
    2. Claggett B,
    3. Diaz R, et al. ELIXA Investigators
    . Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015; 373(23):2247–2257. doi:10.1056/NEJMoa1509225
    OpenUrlCrossRefPubMed
  52. ↵
    1. Holman RR,
    2. Bethel MA,
    3. Mentz RJ, et al. EXSCEL Study Group
    . Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2017; 377(13):1228–1239. doi:10.1056/NEJ-Moa1612917
    OpenUrlCrossRefPubMed
  53. ↵
    1. Fajans SS,
    2. Floyd JC,
    3. Tattersall RB,
    4. Williamson JR,
    5. Pek S,
    6. Taylor CI
    . The various faces of diabetes in the young: changing concepts. Arch Intern Med 1976; 136(2):194–202. pmid:1247351
    OpenUrlCrossRefPubMed
  54. ↵
    1. Tattersall R
    . Maturity-onset diabetes of the young: a clinical history. Diabet Med 1998; 15(1):11–14. doi:10.1002/(SICI)1096-9136(199801)15:1<11::AID-DIA561>3.0.CO;2-0
    OpenUrlCrossRefPubMed
  55. ↵
    1. Hoogwerf BJ,
    2. Rich SS,
    3. Barbosa JJ
    . Meal-stimulated C-peptide and insulin antibodies in type I diabetic subjects and their nondiabetic siblings characterized by HLA-DR antigens. Diabetes 1985; 34(5):440–445. doi:10.2337/diab.34.5.440
    OpenUrlAbstract/FREE Full Text
  56. ↵
    1. Madsbad S,
    2. Faber OK,
    3. Binder C,
    4. McNair P,
    5. Christiansen C,
    6. Transbol I
    . Prevalence of residual beta-cell function in insulin-dependent diabetics in relation to age at onset and duration of diabetes. Diabetes 1978; 27(suppl 1):262–264. doi:10.2337/diab.27.1.s262
    OpenUrlAbstract/FREE Full Text
  57. ↵
    1. Chiquette E,
    2. Oral EA,
    3. Garg A,
    4. Araujo-Vilar D,
    5. Dhankhar P
    . Estimating the prevalence of generalized and partial lipodystrophy: findings and challenges. Diabetes Metab Syndr Obes 2017; 10:375–383. doi:10.2147/DMSO.S130810
    OpenUrlCrossRef

This article requires you to have a ccjm.org account to view the full text. If you already have an account, you may log in below to view this article along with all other CCJM content. If you do not have an account, register here. It’s free!

Back to top

Registration is Now Required for Free Access to CCJM Content

Register once and log in for full access to articles and content. Click “Register” in the upper right corner and follow the simple instructions to create a new account.

If you are using a mobile device, click on the settings icon to access the Register link.

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section